Sandoz looks for solutions

As he seeks to spell out a compelling vision for Novartis after a few months at the helm, chief executive officer Vas Narasimhan is evidently keen to be honest with investors. Among the Swiss group’s weaknesses, he lists “sustainably managing broad diversification”, “integrating non-innovative medicine acquisitions” and pursuing “cost leadership to aggressively take cost out year-on-year”.